Rezolute oral DME therapy shows promise in mid-stage trial
2024-05-24
临床结果上市批准临床2期临床1期
Rezolute has announced positive results from its phase 2 clinical study of RZ402, an oral therapy for diabetic macular edema (DME).
The study met its primary endpoints, demonstrating a significant reduction in central subfield thickness and a favorable safety profile. This marks the first oral treatment to show effectiveness in reducing macular edema, indicating potential for early intervention in DME.
RZ402, a selective plasma kallikrein inhibitorplasma kallikrein inhibitor, was evaluated in a 12-week study involving 94 participants. The trial showed significant CST reduction at all dosage levels, with the 200 mg dose exhibiting the most pronounced effect. The drug was well-tolerated, with adverse events being generally mild and comparable to placebo.
Currently, anti-vascular endothelial growth factor (anti-VEGF) injections are the standard treatment for DME, requiring regular administration and often associated with serious side effects. RZ402, as an oral therapy, could offer a less invasive alternative, addressing both eyes and potentially improving long-term outcomes by allowing earlier intervention.
Recently, the FDA approved two interchangeable biosimilars to Regeneron's Eylea: Biocon Biologics' Yesafili and Samsung Bioepis and Biogen's Opuviz. Both are VEGF inhibitors approved for treating neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。